Actuate Therapeutics Secures $21.7 Million to Support Phase I/II Clinical Trial BioSpace By John Harbison|2019-05-18T15:42:27-08:00May 17, 2019|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Actuate Therapeutics Secures $21.7 Million to Support Phase I/II Clinical Trial Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkXingEmail About the Author: John Harbison Related Posts
